Cardiovascular, kidney and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.